You are so wrong!!! Durata BODs cannot solicit for a higher offer but there is nothing in the offer clause that can prevent any other company from coming in with a much higher offer. Any other company can still come in with a higher "unsolicited" offer. In my opinion, this is only the beginning. Based on the value and effectiveness of this drug, I expect more offers at much higher price. I am buying more DRTX. The risk reward could be huge in my favor.
Mr. Reed also said during the Bloomberg interview that he’s restructured AMD’s debt so it’s no longer burning through cash reserves and is delivering predictable sales growth and improved profitability!!!!! Why is no one on this board paid any attention (ignored) this very positive and important comment???
I interpret this comment to mean that Mr. Reed is telling us that the AMD profits will continue to improve going forward before the arrival of the new brand new technologies. You can imagine what will happened after the introduction of the new technologies.
I trust his words and I will stay long and accumulate more on the way up or during bumps on the road if we wait to load up until for the new AMD technologies hit the market, the price of AMD stock most likely be double or much higher that it is today. I already control over 100,000 shares and I am not afraid. "Patience and persistence are man's greatest virtues." Don't let the wall street thieves and bashers scare you out and steal your shares away from you. Mr. Reed has a lot more to gain from a higher stock price than any one of us on this board and I am confident that he will succeed. He is no rookie in this game. I have faith that he will be proven right and he will burn all the short sellers!
Sentiment: Strong Buy
I think so.. They no longer compete much with AMD. Intel would want to buy them for their ATI graphics so that they can eliminate their reliance on NVDA.
Sorry you feel that way about competition. Intel's tactics have pushed AMD to innovate and overcome those types of tactics. Eastman Kodak stopped innovating and resorted to competitive practices to run other film makers out of business. In the end, it all backfired on them and they are no longer in existence. Intel better start innovating instead of undercutting everyone in order to preserve market share.
They can afford to buy AMD out and they most likely will to protect their position. They already own close to 25%.
Wait until after the class action lawsuits are announced. Investors lost a lot of money (probably billions) due to this screw up and attorneys are probably getting their ammunition ready to start firing.
Be very careful! Past performance does not guarantee future results. If you are up $47K, you may ant to take the profit off the table and have some fun with it. You never go broke by taking a little profit once in a while.
Consider yourself luck. FDA approval is imminent and the stock is headed much higher. Once a week antibiotic is a major advance in therapy.
In my opinion, the stock is headed much higher than current levels.
Sentiment: Strong Buy
The only thing that can save Affymax if the investigation reveals that AMGN may have been involved in foul play in an effort to destroy Omontys. There was billions of dollars at stake here and anything is possible.
The dreamliners are made mainly made with plastic. Very little aluminum. This is actually bad news for Alcoa.
Based on BHPs price per share and revenue per share, AA should be trading around $60.00 per share. Am I missing something? How can BHP generate 14.4% net profit margin and AA only 1%. See stats below from Yahoo Finance. This tells me that either BHP is significantly overvalued or AA has a huge upside potential (10x the current price) if AA can manage to increase the profit margin on its revenue even by a a small fraction of that reported by BHP.
Both companies generate approximately the same revenue per share. However, for some unexplained reason, BHP genrates much higher profit margin. Since both companies are in similar business, one would expect similar profit margins. This variance is difficult to understand/explain, especially since BHPs debt load is 37% higher than AAs.
In my opinion, based on the stat below, Based on revenue and debt comparisons, AA should be trading for $60 per share or higher than BHP. Yes the profit margin variance needs to be expalined but if AA can make even a small improvement in net profit margin, its stock price could skyrocket, maybe not to $60 per share but signifcantly higher than where it is today.
Comments and your opinion are welcomed.
From Yahoo Finance:
BHP's gross revenue per share =$25.17
Net profit per share (EPS) = $3.60 (14.4% profit margin)
Debt = $35.48 billion or $13.33 per share (37.5% higher than AAs debt)
Cash on hand per share = $1.98
BHP stock price per share = $63.63 (760% higher than AA)
AA revenue per share = $22.03
Net profit (EPS) =$0.23 (generates only 1% profit margin)
Debt $8.92 billion or $8.33 per share (37.5% less than BHPs debt)
Cash on hand per share = $1.45 (24% less than BHP)
AA stock price per share = $8.36 (760% cheaper than BHP)
Only miniscule volume of 2700 shares. Most likely someone short on the stock dumbed to create panic at the open. Look at the ask price only 100 shars for sale at 1.89. I am not concened about the premarket action.
You isinterpreted my message. I did not say that AFFY will file for BK. I implied that the only buyer most likely will be Takeda if no BK.
Why would anyone start a biddig war prior to BK? If a bidding war breaks up prir to BK, then the buyer will assume all the liabilities, and that is not likely to happen. Only Takeda will not be absolved of the liabilities after BK since they already owned part of O
When socks at all time highs, grading companies upgrade, as was the case before the market collapse in 2008. When stocks are at their low and improving, they come out with downgrades. In my opinion, it's best to buy when they downgrade and get out when they upgrade. Don't make your investment decisions based on their upgrades/downgrades. History tells us that they have zero credibility and they are often, if not always, wrong.
Amgen or another drug company my still be able to step in and buy AFFY for a much better deal. It's incomprehenible to me that AMGN has not already done so. They can easily do it via a stock swap of 10 share of AFFY to one share or less AMGN. This would only increase the number of outstanding AMGN shares by less tha 4 million 0.5%) shares, which would result in a very tiny dilution to the current AMGN outstanding shares and they would have to pay no cash for the transaction. AMGN can ensure that O will never compete with their Aranesp and Epogen in the US even if Taketa gets FDA approval to reintroduce. However, if it gets reintroduced, AMGN will own it in the US and will still receive royalties from Takeda for its use outside the US. It's a no brainer win-win action for AMGN to take and will also be good for AMGN shareholders because it will either eliminate competition with their Aranesp and Epgogen or worst case scenario they will end up owning Omontys if it gets cleared by the FDA.